Genetics of Pancreatic Cancer and Its Implications on Therapy

Surgical Clinics of North America

Volumn 96, Issue 6, 2016, Pages 1207-1221

  Tatarian, Talar ^a   Winter, Jordan M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Genetics; Pancreatic cancer; Personalized medicine; Targeted therapy

Indexed keywords

B RAF KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEMCITABINE; ISOCITRATE DEHYDROGENASE 1; K RAS PROTEIN; OLAPARIB; TRASTUZUMAB; VEMURAFENIB;

AXON; BRAF GENE; CANCER CHEMOTHERAPY; CANCER GENETICS; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CHROMATIN; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA REPAIR; EGFR GENE; GENE ACTIVATION; GENE MUTATION; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; IDH1 GENE; MUTATION RATE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; VALIDATION STUDY; DISEASE MANAGEMENT; GENETICS; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; TUMOR GENE;

COMBINED MODALITY THERAPY; DISEASE MANAGEMENT; GENES, NEOPLASM; HUMANS; PANCREATIC NEOPLASMS;

EID: 84996479897     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2016.07.014     Document Type: Review

References (80)

1. 1 Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66:1 (2016), 7–30.
2. 2 Rahib, L., Smith, B.D., Aizenberg, R., et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74:11 (2014), 2913–2921.
3. 3 Maitra, A., Adsay, N.V., Argani, P., et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16:9 (2003), 902–912.
4. 4 Winter, J.M., Maitra, A., Yeo, C.J., Genetics and pathology of pancreatic cancer. HPB (Oxford) 8:5 (2006), 324–336.
5. 5 Hansel, D.E., Kern, S.E., Hruban, R.H., Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 4 (2003), 237–256.
6. 6 Iacobuzio-Donahue, C.A., van der Heijden, M.S., Baumgartner, M.R., et al. Large-scale allelotype of pancreaticobiliary carcinoma provides quantitative estimates of genome-wide allelic loss. Cancer Res 64:3 (2004), 871–875.
7. 7 Mahlamaki, E.H., Hoglund, M., Gorunova, L., et al. Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Genes Chromosomes Cancer 20:4 (1997), 383–391.
8. 8 Curtis, L.J., Li, Y., Gerbault-Seureau, M., et al. Amplification of DNA sequences from chromosome 19q13.1 in human pancreatic cell lines. Genomics 53:1 (1998), 42–55.
9. 9 Hidalgo, M., Von Hoff, D.D., Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 18:16 (2012), 4249–4256.
10. 10 Smit, V.T., Boot, A.J., Smits, A.M., et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 16:16 (1988), 7773–7782.
11. 11 Hruban, R.H., Iacobuzio-Donahue, C., Wilentz, R.E., et al. Molecular pathology of pancreatic cancer. Cancer J 7:4 (2001), 251–258.
12. 12 Kranenburg, O., The KRAS oncogene: past, present, and future. Biochim Biophys Acta 1756:2 (2005), 81–82.
13. 13 Collins, M.A., Pasca di Magliano, M., Kras as a key oncogene and therapeutic target in pancreatic cancer. Front Physiol, 4, 2013, 407.
14. 14 Caldas, C., Hahn, S.A., da Costa, L.T., et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:1 (1994), 27–32.
15. 15 Schutte, M., Hruban, R.H., Geradts, J., et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 57:15 (1997), 3126–3130.
16. 16 Taylor, W.R., Stark, G.R., Regulation of the G2/M transition by p53. Oncogene 20:15 (2001), 1803–1815.
17. 17 Hahn, S.A., Schutte, M., Hoque, A.T., et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:5247 (1996), 350–353.
18. 18 Yoo, J., Ghiassi, M., Jirmanova, L., et al. Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. J Biol Chem 278:44 (2003), 43001–43007.
19. 19 Embuscado, E.E., Laheru, D., Ricci, F., et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 4:5 (2005), 548–554.
20. 20 Crane, C.H., Varadhachary, G.R., Yordy, J.S., et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 29:22 (2011), 3037–3043.
21. 21 Iacobuzio-Donahue, C.A., Fu, B., Yachida, S., et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:11 (2009), 1806–1813.
22. 22 Winter, J.M., Tang, L.H., Klimstra, D.S., et al. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression. Ann Surg 258:2 (2013), 331–335.
23. 23 Jones, S., Zhang, X., Parsons, D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:5897 (2008), 1801–1806.
24. 24 Biankin, A.V., Waddell, N., Kassahn, K.S., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:7424 (2012), 399–405.
25. 25 Waddell, N., Pajic, M., Patch, A.M., et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:7540 (2015), 495–501.
26. 26 Wu, J., Jiao, Y., Dal Molin, M., et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A 108:52 (2011), 21188–21193.
27. 27 Wong, S.Q., Li, J., Tan, A.Y., et al. Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics, 7, 2014, 23.
28. 28 Kern, S.E., Winter, J.M., Elegance, silence and nonsense in the mutations literature for solid tumors. Cancer Biol Ther 5:4 (2006), 349–359.
29. 29 Winter, J.M., Brody, J.R., Kern, S.E., Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature. Cancer Biol Ther 5:4 (2006), 360–370.
30. 30 Ma, Y., Dai, H., Kong, X., Impact of warm ischemia on gene expression analysis in surgically removed biosamples. Anal Biochem 423:2 (2012), 229–235.
31. 31 Fleige, S., Pfaffl, M.W., RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 27:2–3 (2006), 126–139.
32. 32 Spruessel, A., Steimann, G., Jung, M., et al. Tissue ischemia time affects gene and protein expression patterns within minutes following surgical tumor excision. Biotechniques 36:6 (2004), 1030–1037.
33. 33 Valero, V. 3rd, Saunders, T.J., He, J., et al. Reliable detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing: implications for surgical management. Ann Surg 263:1 (2016), 153–161.
34. 34 Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med 330:12 (1994), 820–825.
35. 35 Iqbal, N., Iqbal, N., Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int, 2014, 2014, 852748.
36. 36 Marty, M., Cognetti, F., Maraninchi, D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23:19 (2005), 4265–4274.
37. 37 Swain, S.M., Baselga, J., Kim, S.B., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:8 (2015), 724–734.
38. 38 Robert C, Karaszewska B, Schachter J, et al. Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib and trametinib with vemurafenib as first-line therapy in patients with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. The European Cancer Congress 2015. 2015. Available at: https://www.europeancancercongress.org/Vienna2015/Scientific-Programme/Searchable-Programme?trackid=00181-anchorScpr. Accessed February 26, 2016.
39. 39 Chapman, P.B., Hauschild, A., Robert, C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:26 (2011), 2507–2516.
40. 40 Shigematsu, H., Lin, L., Takahashi, T., et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:5 (2005), 339–346.
41. 41 Prabhakar, C.N., Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Cancer Res 4:2 (2015), 110–118.
42. 42 Zhou, C., Wu, Y.L., Chen, G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:8 (2011), 735–742.
43. 43 Menard, S., Casalini, P., Campiglio, M., et al. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 12:Suppl 1 (2001), S15–S19.
44. 44 Hudis, C.A., Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:1 (2007), 39–51.
45. 45 Bang, Y.J., Van Cutsem, E., Feyereislova, A., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:9742 (2010), 687–697.
46. 46 Harder, J., Ihorst, G., Heinemann, V., et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 106:6 (2012), 1033–1038.
47. 47 Moore, M.J., Goldstein, D., Hamm, J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:15 (2007), 1960–1966.
48. 48 Wang, J.P., Wu, C.Y., Yeh, Y.C., et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget 6:20 (2015), 18162–18173.
49. 49 Van Cutsem, E., Kohne, C.H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:14 (2009), 1408–1417.
50. 50 Fensterer, H., Schade-Brittinger, C., Muller, H.H., et al. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann Oncol 24:10 (2013), 2576–2581.
51. 51 Van Cutsem, E., van de Velde, H., Karasek, P., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:8 (2004), 1430–1438.
52. 52 Moskaluk, C.A., Hruban, R.H., Kern, S.E., p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 57:11 (1997), 2140–2143.
53. 53 Hruban, R.H., Wilentz, R.E., Kern, S.E., Genetic progression in the pancreatic ducts. Am J Pathol 156:6 (2000), 1821–1825.
54. 54 Hingorani, S.R., Wang, L., Multani, A.S., et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7:5 (2005), 469–483.
55. 55 Mologni, L., Dekhil, H., Ceccon, M., et al. Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res 70:18 (2010), 7253–7263.
56. 56 Pecot, C.V., Wu, S.Y., Bellister, S., et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther 13:12 (2014), 2876–2885.
57. 57 Zorde Khvalevsky, E., Gabai, R., Rachmut, I.H., et al. Mutant KRAS is a druggable target for pancreatic cancer. Proc Natl Acad Sci U S A 110:51 (2013), 20723–20728.
58. 58 Shi, X.H., Liang, Z.Y., Ren, X.Y., et al. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther 16:3 (2009), 227–236.
59. 59 Hyman, D.M., Puzanov, I., Subbiah, V., et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:8 (2015), 726–736.
60. 60 Calhoun, E.S., Jones, J.B., Ashfaq, R., et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol 163:4 (2003), 1255–1260.
61. 61 Hahn, S.A., Greenhalf, B., Ellis, I., et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:3 (2003), 214–221.
62. 62 Farmer, H., McCabe, N., Lord, C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:7035 (2005), 917–921.
63. 63 Ashworth, A., A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 26:22 (2008), 3785–3790.
64. 64 Hucl, T., Rago, C., Gallmeier, E., et al. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res 68:13 (2008), 5023–5030.
65. 65 Ledermann, J., Harter, P., Gourley, C., et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 366:15 (2012), 1382–1392.
66. 66 Mateo, J., Carreira, S., Sandhu, S., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:18 (2015), 1697–1708.
67. 67 van der Heijden, M.S., Brody, J.R., Dezentje, D.A., et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:20 (2005), 7508–7515.
68. 68 Lowery, M.A., Kelsen, D.P., Stadler, Z.K., et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 16:10 (2011), 1397–1402.
69. 69 Conroy, T., Desseigne, F., Ychou, M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:19 (2011), 1817–1825.
70. 70 Von Hoff, D.D., Ervin, T., Arena, F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:18 (2013), 1691–1703.
71. 71 Golan, T., Kanji, Z.S., Epelbaum, R., et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers. Br J Cancer 111:6 (2014), 1132–1138.
72. 72 Sonnenblick, A., Kadouri, L., Appelbaum, L., et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 12:3 (2011), 165–168.
73. 73 Benafif, S., Hall, M., An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther 8 (2015), 519–528.
74. 74 Lowery, M., Shah, M.A., Smyth, E., et al. A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma. J Gastrointest Cancer 42:3 (2011), 160–164.
75. 75 Vyas, O., Leung, K., Ledbetter, L., et al. Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation. Anticancer Drugs 26:2 (2015), 224–226.
76. 76 Bendell, J., O'Reilly, E.M., Middleton, M.R., et al. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer. Ann Oncol 26:4 (2015), 804–811.
77. 77 Kaufman, B., Shapira-Frommer, R., Schmutzler, R.K., et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 33:3 (2015), 244–250.
78. 78 Nomi, T., Sho, M., Akahori, T., et al. Clinical significant and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13:7 (2007), 2151–2157.
79. 79 Beatty, G.L., Chiorean, E.G., Fishman, M.P., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:6024 (2011), 1612–1616.
80. 80 Stromnes, I.M., Schmitt, T.M., Hulbert, A., et al. T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell 28:5 (2015), 638–652.